Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Schmidt

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 5, 2010
An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporterJohn A Lowe, Shari L Deninno, Susan E Drozda, et al.
ACS Chemical Biology|October 9, 2014
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environmentJan-Philip Schülke, Laura A McAllister, Kieran F Geoghegan, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|July 26, 2006
Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian speciesTimothy M Coskran, Daniel Morton, Frank S Menniti, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 10, 2015
Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathwaysFernando E Padovan-Neto, Stephen Sammut, Shreaya Chakroborty, et al.
Neuropharmacology|June 20, 2006
Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosisJudith A Siuciak, Douglas S Chapin, John F Harms, et al.
Brain Research|January 22, 2019
In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [<sup>18</sup>F]MNI-659Marie M Svedberg, Katarina Varnäs, Andrea Varrone, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 7, 2010
Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's diseaseRobin J Kleiman, Lida H Kimmel, Susan E Bove, et al.
Neuropharmacology|June 14, 2006
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal functionJudith A Siuciak, Sheryl A McCarthy, Douglas S Chapin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 2013
Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574Christopher L Shaffer, Raymond S Hurst, Renato J Scialis, et al.
Journal of Medicinal Chemistry|January 19, 2007
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitorsThomas A Chappie, John M Humphrey, Martin P Allen, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|January 5, 2010
An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporterJohn A Lowe, Shari L Deninno, Susan E Drozda, et al.
ACS Chemical Biology|October 9, 2014
Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environmentJan-Philip Schülke, Laura A McAllister, Kieran F Geoghegan, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|July 26, 2006
Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian speciesTimothy M Coskran, Daniel Morton, Frank S Menniti, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 10, 2015
Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathwaysFernando E Padovan-Neto, Stephen Sammut, Shreaya Chakroborty, et al.
Neuropharmacology|June 20, 2006
Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosisJudith A Siuciak, Douglas S Chapin, John F Harms, et al.
Brain Research|January 22, 2019
In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [<sup>18</sup>F]MNI-659Marie M Svedberg, Katarina Varnäs, Andrea Varrone, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 7, 2010
Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's diseaseRobin J Kleiman, Lida H Kimmel, Susan E Bove, et al.
Neuropharmacology|June 14, 2006
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal functionJudith A Siuciak, Sheryl A McCarthy, Douglas S Chapin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 2013
Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574Christopher L Shaffer, Raymond S Hurst, Renato J Scialis, et al.
Journal of Medicinal Chemistry|January 19, 2007
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitorsThomas A Chappie, John M Humphrey, Martin P Allen, et al.
Pageof 5